Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (CONVERT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01027065|
Recruitment Status : Unknown
Verified October 2012 by Cytheris SA.
Recruitment status was: Active, not recruiting
First Posted : December 7, 2009
Last Update Posted : October 18, 2012
|Condition or disease||Intervention/treatment||Phase|
|Chronic Hepatitis B||Drug: CYT107+GenHevac+entecavir or tenofovir Drug: CYT107+ entecavir or tenofovir||Phase 1 Phase 2|
This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107) in HBeAg-negative chronic hepatitis B infected adult patients. The dose escalation is aimed at establishing the safety of a biologically active doses of CYT107 added to the current antiviral therapy with entecavir or tenofovir and vaccination or not. At each dose level, study patients will receive one subcutaneous administration of CYT107 per week for a total of 4.
Groups of 8 patients will be entered at each dose level of CYT107. Three dose levels are planned.
At each dose level, patients are randomized between 2 arms of treatment: tritherapy (CYT107, vaccine and antiviral treatment) or bitherapy (CYT107 and vaccine). Each treatment group is composed of 4 patients, 3 receiving experimental treatments, 1 just the current antiviral treatment (control patient).
According to the treatment arm, eligible patients initially receive a vaccine if in treatment group of tritherapy, thereafter, CYT107 is added for a cycle of four weekly injections (if not a control patient) at a defined dose level. If in treatment group of tritherapy, patients will receive 2 additional doses of vaccine.
The treatment phase for the tritherapy group is from first vaccine D0 to last vaccine W12 and includes CYT107 administration from W4 to W7.
The treatment phase for the bitehrapy group is from W4 to W7 corresponding to CYT104 injections.
The patients are then followed on a regular basis until reaching 52 weeks after the D0.
Participants will have 1 overnight hospitalization and 12 clinic visit on a period of 55 weeks.
During the visits the following may be done:
- medical history, physical examination, blood tests
- electrocardiograms (ECG)
- chest X-Ray
- liver/spleen imaging
- urine tests
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients|
|Study Start Date :||December 2009|
|Estimated Primary Completion Date :||November 2012|
|Estimated Study Completion Date :||March 2013|
|Experimental: Tritherapy: CYT107+ vaccine+ antiviral||
Drug: CYT107+GenHevac+entecavir or tenofovir
4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
|Experimental: Bitherapy: CYT107 + antiviral||
Drug: CYT107+ entecavir or tenofovir
4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
- To determine the short and long-term safety and biological activity of CYT107 in patients with a HBeAg-negative chronic hepatitis B who have, at screening a HBV DNA undetectable stable for at least 3 months with antiviral treatment. [ Time Frame: Week 12 ]
- To characterize the pharmacokinetics and pharmacodynamics of CYT107 in humans chronically infected with HBV. [ Time Frame: Week 12 ]
- To assess the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the markers of the HBV infection (antiviral activity)at W16 weeks and W52 [ Time Frame: Week 12 and Week 52 ]
- To quantify the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the immune system at W16 weeks [ Time Frame: Week 16 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01027065
|Hopital Henri Mendor-Service d'HepatoGastroEnterologie|
|Hopital de l'Hotel Dieu|
|Hopital Saint Joseph|
|Azienda Ospedaliero-Universitaria, Policlinico Sant'Orsola Malpighi|
|Study Chair:||Christophe Hezode||Hopital Henri Mondor-Créteil-France|
|Principal Investigator:||Pietro Andreone||S. Orsola Malpighi- Bologna-Italy|